Use the hyperlinks, where available to access additional clinical trial information.
A Multicenter, Double-Blind, Randomized Phase 3 Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo, in Combination With Chemotherapy, for First-Line Treatment of Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma
Innovent Biologics (Suzhou) Co. Ltd.
Eligible patients will be randomised to receive either a placebo or Sintilimab targeted therapy, given in combination with the investigator's choice of chemotherapy.